Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 2;12(2):45-53.
doi: 10.1055/s-0042-1749612. eCollection 2022 Apr.

Zinc, Magnesium, and Copper Levels in Patients with Sickle Cell Disease: A Systematic Review and Meta-analysis

Ibrahim H Elkhidir  1 , Shahd S Ali  1 , Waad K Ali  1 , Hind R Madani  1 , Rawya A Basheir  1 , Rayan M Altayeb  1 , Rayan H S Shazali  1 , Safaa Fadlelmoula  1 , Wisal M Eltayeb  1 , Zeina I Omar  1 , Mahmoud Elnil  1 , Sagad O O Mohamed  1
Affiliations
Review

Zinc, Magnesium, and Copper Levels in Patients with Sickle Cell Disease: A Systematic Review and Meta-analysis

Ibrahim H Elkhidir et al. Avicenna J Med. .

Abstract

Background Sickle cell disease (SCD) is associated with oxidative stress due to an imbalance between production and elimination of the reactive oxygen species. It has been reported that SCD patients are at risk of multiple micronutrients' deficiencies, including several trace elements involved in the antioxidation mechanisms. We aimed to assess the status of these micronutrients in SCD patients. Methods This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The databases of MedLine, Embase, and PsycInfo were used for the systematic search from time the databases existed until April 2021. A total of 36 studies fulfilled the eligibility criteria. We calculated the pooled standardized mean difference (SMD) of serum zinc, magnesium, or copper levels among patients with SCD and their healthy controls. Results SCD patients had significantly lower zinc (SMD = -1.27 [95% CI: 1.67-0.87, p 0.001]) and magnesium levels (SMD = -0.53 [95% CI: 1.0-0.06, p 0.026] than their controls. Copper level was found to be significantly higher in SCD patients, with SMD = 0.68 (95% CI: 0.05-1.32, p 0.004). Conclusion This review showed that SCD patients may potentially prompt to have lower zinc and magnesium levels and higher copper levels compared with those without the disease. Future research need to be directed to investigate clinical outcome of nutritional difficiencies in patients with SCD, as well as the possibility of implementing nutritional supplement programs which may help minimizing the harmful effects of the disease on human body.

Keywords: SCD; copper; magnesium; sickle cell; zinc.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Figures

Fig. 1
Fig. 1
The flow diagram for the process of study selection.
Fig. 2
Fig. 2
Pooled SMD of zinc levels among patients with SCD. CI, confidence interval; SCD, sickle cell disease; SD, standard deviation; SMD, standardadized mean difference.
Fig. 3
Fig. 3
Pooled SMD of magnesium levels among patients with SCD. CI, confidence interval; SCD, sickle cell disease; SD, standard deviation; SMD, standardadized mean difference.
Fig. 4
Fig. 4
Pooled SMD of copper levels among patients with SCD. CI, confidence interval; SCD, sickle cell disease; SD, standard deviation; SMD, standardadized mean difference.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chakravorty S, Williams T N. Sickle cell disease: a neglected chronic disease of increasing global health importance. Arch Dis Child. 2015;100(01):48–53. - PMC - PubMed
    1. Brousse V, Makani J, Rees D C. Management of sickle cell disease in the community. BMJ. 2014;348:g1765. - PMC - PubMed
    1. Wastnedge E, Waters D, Patel S. The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis. J Glob Health. 2018;8(02):21103. - PMC - PubMed
    1. Farooq S, Testai F D. Neurologic complications of sickle cell disease. Curr Neurol Neurosci Rep. 2019;19(04):17. - PubMed
    1. Pinto V M, Balocco M, Quintino S, Forni G L. Sickle cell disease: a review for the internist. Intern Emerg Med. 2019;14(07):1051–1064. - PubMed